Welcome!

News Feed Item

In the Highly Competitive MRSA cSSSI Market, Cubist's Sivextro Will be Positively Differentiated from Current and Emerging Therapies

Lipoglycopeptides Dalvance and Oritavancin Will Find Favorable Uptake as Convenient Outpatient Anti-MRSA Agents, According to Findings from Decision Resources Group

BURLINGTON, Mass., April 3, 2014 /PRNewswire/ -- Decision Resources Group finds that following its launch, Cubist's second generation oxazolidinone Sivextro will be highly differentiated from other anti-MRSA (methicillin-resistant Staphylococcus aureus) agents for the treatment of complicated skin and skin structure infections (cSSSIs) due to MRSA. In particular, Sivextro's once-daily dosing, shorter course of therapy, and its potential for lower treatment-related adverse events are notable improvements over Pfizer's Zyvox/Zyvoxid, the current market share leader for MRSA cSSSIs. Accordingly, in March 2014, the FDA's Anti-Infective Drugs Advisory Committee unanimously recommended Sivextro's approval for the treatment of cSSSIs.

Decision Resources Group Logo

Other key findings from the DecisionBase report entitled Methicillin-Resistant Staphylococcus Aureus Complicated Skin and Skin Structure Infections: In The Crowded MRSA cSSSI Market, How Will Emerging Therapies Differentiate Themselves from Current Standard of Care?:

  • Importance of early clinical response rates for MRSA cSSSIs: Less than 40 percent of surveyed European infectious disease (ID) specialists chose early clinical response rate among their top three most persuasive end points when evaluating new antibiotics for MRSA cSSSIs, compared with nearly 60 percent of surveyed U.S. ID specialists who ranked this end point accordingly. This finding highlights the impact of the FDA's recommendation for use of early response as the primary end point in clinical trials.
  • Payer receptivity to new anti-MRSA agents with a shorter length of therapy: As U.S. hospitals aim to contain healthcare costs, hospital pharmacy directors will seek therapies that help reduce the cost of managing MRSA cSSSIs, including agents that promote earlier discharge. Nearly two-thirds of surveyed pharmacy directors support formulary inclusion of agents with a shorter course of therapy than Zyvox/Zyvoxid, and are priced similarly or at a premium to a seven-day course of Zyvox/Zyvoxid.
  • Future impact of Dalvance and oritavancin on current therapies: Surveyed ID specialists indicate that Durata's Dalvance and The Medicines Company's oritavancin will gain uptake at the expense of vancomycin and Cubist's Cubicin. With long systemic half-lives allowing for convenient once-weekly or single dosing, respectively, we expect both agents will compete for MRSA cSSSI patients who require further antibiotic therapy at discharge or are candidates for outpatient parenteral antibiotic therapy.

Comments from Decision Resources Group Analyst Maria Ascano Ph.D.:

  • "Although ID specialists consider efficacy to be the most important drug attribute for treating MRSA cSSSIs, the availability of many highly effective therapies will make it difficult for new entrants to differentiate themselves on efficacy improvements alone. However, because this segment of the market is dominated by older less well-tolerated parenteral antibiotics, developers can highlight safety and delivery improvements to capitalize on market opportunities."
  • "Therapies that can help promote early discharge or reduce hospital admissions will gain favorable uptake as healthcare providers aim to reduce hospital-associated costs. Therefore, agents providing convenient use in the outpatient setting, including availability in IV and oral formulations, shorter courses of therapy, or infrequent dosing, will be highly differentiated in this crowded market segment."

About Decision Resources Group
Decision Resources Group offers best-in-class, high-value information and insights on critical issues within the healthcare industry. Clients rely on this analysis and data to make informed decisions. Find out more at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
[email protected]

Logo - http://photos.prnewswire.com/prnh/20130103/MM36768LOGO

SOURCE Decision Resources Group

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science" is responsible for guiding the technology strategy within Hitachi Vantara for IoT and Analytics. Bill brings a balanced business-technology approach that focuses on business outcomes to drive data, analytics and technology decisions that underpin an organization's digital transformation strategy.
A valuable conference experience generates new contacts, sales leads, potential strategic partners and potential investors; helps gather competitive intelligence and even provides inspiration for new products and services. Conference Guru works with conference organizers to pass great deals to great conferences, helping you discover new conferences and increase your return on investment.
Headquartered in Plainsboro, NJ, Synametrics Technologies has provided IT professionals and computer systems developers since 1997. Based on the success of their initial product offerings (WinSQL and DeltaCopy), the company continues to create and hone innovative products that help its customers get more from their computer applications, databases and infrastructure. To date, over one million users around the world have chosen Synametrics solutions to help power their accelerated business or per...
DXWorldEXPO LLC announced today that ICOHOLDER named "Media Sponsor" of Miami Blockchain Event by FinTechEXPO. ICOHOLDER gives detailed information and help the community to invest in the trusty projects. Miami Blockchain Event by FinTechEXPO has opened its Call for Papers. The two-day event will present 20 top Blockchain experts. All speaking inquiries which covers the following information can be submitted by email to [email protected] Miami Blockchain Event by FinTechEXPOalso offers sp...
Sanjeev Sharma Joins November 11-13, 2018 @DevOpsSummit at @CloudEXPO New York Faculty. Sanjeev Sharma is an internationally known DevOps and Cloud Transformation thought leader, technology executive, and author. Sanjeev's industry experience includes tenures as CTO, Technical Sales leader, and Cloud Architect leader. As an IBM Distinguished Engineer, Sanjeev is recognized at the highest levels of IBM's core of technical leaders.
SYS-CON Events announced today that IoT Global Network has been named “Media Sponsor” of SYS-CON's @ThingsExpo, which will take place on June 6–8, 2017, at the Javits Center in New York City, NY. The IoT Global Network is a platform where you can connect with industry experts and network across the IoT community to build the successful IoT business of the future.
DXWorldEXPO LLC announced today that Kevin Jackson joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Kevin L. Jackson is a globally recognized cloud computing expert and Founder/Author of the award winning "Cloud Musings" blog. Mr. Jackson has also been recognized as a "Top 100 Cybersecurity Influencer and Brand" by Onalytica (2015), a Huffington Post "Top 100 Cloud Computing Experts on Twitter" (2013) and a "Top 50 C...
IoT is rapidly becoming mainstream as more and more investments are made into the platforms and technology. As this movement continues to expand and gain momentum it creates a massive wall of noise that can be difficult to sift through. Unfortunately, this inevitably makes IoT less approachable for people to get started with and can hamper efforts to integrate this key technology into your own portfolio. There are so many connected products already in place today with many hundreds more on the h...
When applications are hosted on servers, they produce immense quantities of logging data. Quality engineers should verify that apps are producing log data that is existent, correct, consumable, and complete. Otherwise, apps in production are not easily monitored, have issues that are difficult to detect, and cannot be corrected quickly. Tom Chavez presents the four steps that quality engineers should include in every test plan for apps that produce log output or other machine data. Learn the ste...
The best way to leverage your Cloud Expo presence as a sponsor and exhibitor is to plan your news announcements around our events. The press covering Cloud Expo and @ThingsExpo will have access to these releases and will amplify your news announcements. More than two dozen Cloud companies either set deals at our shows or have announced their mergers and acquisitions at Cloud Expo. Product announcements during our show provide your company with the most reach through our targeted audiences.
Enterprises are universally struggling to understand where the new tools and methodologies of DevOps fit into their organizations, and are universally making the same mistakes. These mistakes are not unavoidable, and in fact, avoiding them gifts an organization with sustained competitive advantage, just like it did for Japanese Manufacturing Post WWII.
When building large, cloud-based applications that operate at a high scale, it's important to maintain a high availability and resilience to failures. In order to do that, you must be tolerant of failures, even in light of failures in other areas of your application. "Fly two mistakes high" is an old adage in the radio control airplane hobby. It means, fly high enough so that if you make a mistake, you can continue flying with room to still make mistakes. In his session at 18th Cloud Expo, Le...
With more than 30 Kubernetes solutions in the marketplace, it's tempting to think Kubernetes and the vendor ecosystem has solved the problem of operationalizing containers at scale or of automatically managing the elasticity of the underlying infrastructure that these solutions need to be truly scalable. Far from it. There are at least six major pain points that companies experience when they try to deploy and run Kubernetes in their complex environments. In this presentation, the speaker will d...
DevOpsSummit New York 2018, colocated with CloudEXPO | DXWorldEXPO New York 2018 will be held November 11-13, 2018, in New York City. Digital Transformation (DX) is a major focus with the introduction of DXWorldEXPO within the program. Successful transformation requires a laser focus on being data-driven and on using all the tools available that enable transformation if they plan to survive over the long term.
Machine learning provides predictive models which a business can apply in countless ways to better understand its customers and operations. Since machine learning was first developed with flat, tabular data in mind, it is still not widely understood: when does it make sense to use graph databases and machine learning in combination? This talk tackles the question from two ends: classifying predictive analytics methods and assessing graph database attributes. It also examines the ongoing lifecycl...